uniQure annonce une mise à jour des essais cliniques de phase I/II de la thérapie génique AMT-130 pour le traitement de la maladie de Huntington

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean CSF NfL continue to demonstrate favorable trends with low-dose patients Lire la suite...

fr_FRFrench